We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Kidney Biopsy Profiles Predict Delayed Graft Function

By LabMedica International staff writers
Posted on 28 Feb 2018
The probability of renal graft failure can be assessed for donor kidney biopsies through histological analyses; the potential for delayed graft function is not as easily determined by morphology alone, but could potentially be aided by molecular analysis.

A scientific team led by those at Harvard University Office of Technology Development (Cambridge, MA; USA) used donor renal biopsies for both histological assessments and gene expression analysis. More...
RNA was extracted from tissue and reverse transcribed to complementary DNA (cDNA), which was combined with primers designed for genes that were chosen based on literature review related to delayed graft function.

The scientists used quantitative real-time polymerase chain reaction (PCR) to perform gene expression analyses, comparing biopsies from 16 kidneys that showed primary function upon transplantation with those 16 exhibiting delayed graft function. Delayed graft function described the condition of a patient requiring dialysis within a week of transplantation. From the set of genes that the team selected for comparison between the two renal biopsy groups, there were four that showed increased expression within the delayed graft function biopsy samples.

One of the four genes expressed more highly in delayed graft function samples was annotated as a gene for matrix metallopeptidase 3 (MMP3; stromelysin 1, progelatinase), which are related to inflammation and immune response. The other three genes showing more expression with delayed graft function were categorized as related to metabolism, and they were annotated as retinol-binding protein 4, plasma (RBP4); cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4 (CYP3A4); and fatty acid binding protein 1, liver (FABP1). For delayed graft function samples, these four genes showed increased expression from about 2.5- to 4.0-fold each. In comparison, for samples with immediate function, expression of these four genes hovered around 1.0-fold, with some signals slightly below 1.0 or between 1.0- and 2.0-fold.

The authors concluded that the results of their study indicated a possible gene fingerprint, with potential to forecast likelihood of delayed graft function for donor renal tissue. They recommended further research to assess the value of this approach in conjunction with existing protocols. The study was presented at the Annual Cutting Edge of Transplantation (CEOT) Meeting held February 8-10, 2018. Phoenix, AZ, USA.

Related Links:
Harvard University Office of Technology Development


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.